<scp>NYHA</scp> classification for decision‐making in heart failure: Time to reassess?

Zimerman, André; Silveira, Anderson Donelli da; Solomon, Scott D.; Rohde, Luís Eduardo Paim

doi:10.1002/ejhf.2923

Cited by 7 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specific symptoms were strongly associated with physiological, psychological and environmental factors. Daytime dyspnea showed the greatest correlation with NYHA, indicating that more severe dyspnea and lower activity levels were observed in patients with higher NYHA classifications (Zimerman et al, 2023). Psychological factors revealed a significant association between depression and difficulty sleeping, which was consistent with the conclusions of a previous study (Fang et al, 2019).…”

Section: Discussionsupporting

confidence: 90%

Network analysis of symptoms, physiological, psychological and environmental risk factors based on unpleasant symptom theory in patients with chronic heart failure

Wang,

Xu,

et al. 2024

Int J of Nursing Practice

View full text Add to dashboard Cite

BackgroundSomatic symptoms and related factors in patients with chronic heart failure have been extensively researched. However, more insight into the complex interconnections among these constructs is needed, as most studies focus on them independently from each other.AimsThe aim of this study is to gain a comprehensive understanding of how somatic symptoms and related factors are interconnected among patients with chronic heart failure.MethodsA total of 379 patients were enrolled. Network analysis was used to explore the interconnections among the somatic symptoms and related risk factors.ResultsThe four core symptoms of chronic heart failure were daytime dyspnea, dyspnea when lying down, fatigue and difficulty sleeping. Within the network, the edge weights of depression–anxiety, subjective social support–objective social support, and subjective social support–social support availability were more significant than others. Among physiological, psychological and environmental factors, the edge weights of NYHA–dyspnea, depression–difficulty sleeping, and social support availability–dyspnea when lying down were more significant than others. Depression and anxiety had the highest centrality, indicating stronger and closer connections with other nodes.ConclusionsPsychological and environmental factors stood out in the network, suggesting the potential value of interventions targeting these factors to improve overall health.

show abstract

Section: Discussionsupporting

confidence: 90%

Network analysis of symptoms, physiological, psychological and environmental risk factors based on unpleasant symptom theory in patients with chronic heart failure

Wang,

Xu,

et al. 2024

Int J of Nursing Practice

View full text Add to dashboard Cite

show abstract

“…The NYHA functional classification, first introduced in 1921, is frequently used to categorize patients with heart disease based on their symptoms and limitations. 35 An important question to ask is whether patient’s NYHA classification plays a larger role in death status rather than age at CVS or whether they underwent an extraction. Given limited data on this variable, no conclusions can be drawn.…”

Section: Discussionmentioning

confidence: 99%

Oral Health Clearance Outcomes for Cardiovascular Surgery

Zhou,

Viozzi,

Heneberk

et al. 2024

Mayo Clinic Proceedings: Innovations, Quality & Outcomes

View full text Add to dashboard Cite

“…This hospital-based, retrospective, cohort study was conducted at a tertiary care healthcare center in India. Patients aged >18 years, newly diagnosed with HF (NYHA class I-IV) 10 who received Sacubitril/Valsartan treatment (Tab. Sacuval, Alkem Laboratories Ltd.) twice daily for at least three months (Feb-Apr 2023) were obtained.…”

Section: Methodsmentioning

confidence: 99%

Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure in India: A Retrospective Real-world (SAVE) Study

Sachdeva,

Shukla,

Mayabhate

et al. 2024

Indian Journal of Clinical Cardiology

View full text Add to dashboard Cite

Background: Sacubitril/Valsartan is one of the pillars of heart failure (HF) management. Little is known about its uses or impact in real-world practice in the Indian population. We evaluated the effectiveness and Safety of Sacubitril/Valsartan in Heart Failure in India. Methods: This retrospective analysis involved newly diagnosed adult patients of HF (class I–IV, per physician clinical assessment and discretion), treated in a tertiary care hospital during period of February–April 2023 and received Sacubitril/Valsartan. N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measured in addition to demographics, clinical symptoms, comorbidities, and left ventricular ejection fraction (LVEF). Following three months of Sacubitril/Valsartan medication, changes in LVEF, NT-proBNP levels, and clinical symptoms (graded from 1 to 10, with 10 being the maximum severity) were assessed. Results: Out of 60 patients eligible for the study, 57% were males and 43% were females. Mean body weight was 60.26 ± 7.00 kg, while mean BP was 130/81 mmHg. 60% patients had both type 2 diabetes and hypertension as comorbidity. There was 23% improvement in LVEF (from mean LVEF of 34 to 42, P < .0001), with a significant decrease in NT-proBNP levels (mean 1220.5 pg/mL to 118.1 pg/mL, P < .0001) after treatment with Sacubitril/Valsartan for 3 months, resulted in marked improvement in clinical symptoms of breathlessness (mean score decreased from 6 to 2, P < .05), edema (mean score decreased from 5.5 to 1.8, P < .05) and palpitations (mean score decreased from 2.4 to 1.1, P < .05. 50 mg BD was the most commonly used dose of Sacubitril/Valsartan (70% patients), followed by 100 mg BD (25% patients) and rest (5%) with 200 mg BD dose. Treatment with Sacubitril/Valsartan was well tolerated, with <5% patients reporting hypotension. Conclusion: The findings of this real-world study suggest Sacubitril/Valsartan was associated with an increase in ejection fraction translating into symptomatic improvement in Indian patients of HF.

show abstract

NYHA classification for decision‐making in heart failure: Time to reassess?

Cited by 7 publications

References 29 publications

Network analysis of symptoms, physiological, psychological and environmental risk factors based on unpleasant symptom theory in patients with chronic heart failure

Network analysis of symptoms, physiological, psychological and environmental risk factors based on unpleasant symptom theory in patients with chronic heart failure

Oral Health Clearance Outcomes for Cardiovascular Surgery

Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure in India: A Retrospective Real-world (SAVE) Study

Contact Info

Product

Resources

About